These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. Cohen JB; Brown NJ; Brown SA; Dent S; van Dorst DCH; Herrmann SM; Lang NN; Oudit GY; Touyz RM; Hypertension; 2023 Mar; 80(3):e46-e57. PubMed ID: 36621810 [TBL] [Abstract][Full Text] [Related]
4. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Fleming MR; Xiao L; Jackson KD; Beckman JA; Barac A; Moslehi JJ Circ Res; 2021 Jun; 128(12):1973-1987. PubMed ID: 34110908 [TBL] [Abstract][Full Text] [Related]
5. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors. Pineda-Gayoso R; Alomar M; Lee DH; Fradley MG Curr Treat Options Oncol; 2020 Jun; 21(8):67. PubMed ID: 32607825 [TBL] [Abstract][Full Text] [Related]
7. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation. Butel-Simoes LE; Haw TJ; Williams T; Sritharan S; Gadre P; Herrmann SM; Herrmann J; Ngo DTM; Sverdlov AL Hypertension; 2023 Apr; 80(4):685-710. PubMed ID: 36756872 [TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110 [TBL] [Abstract][Full Text] [Related]
9. [Hypertension and cancer : Dangerous Liaisons]. Duvillier P Ann Cardiol Angeiol (Paris); 2022 Nov; 71(5):317-320. PubMed ID: 36075765 [TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165 [TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521 [TBL] [Abstract][Full Text] [Related]
12. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. Hall PS; Harshman LC; Srinivas S; Witteles RM JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801 [TBL] [Abstract][Full Text] [Related]
13. Vascular Complications of Cancer Chemotherapy. Cameron AC; Touyz RM; Lang NN Can J Cardiol; 2016 Jul; 32(7):852-62. PubMed ID: 26968393 [TBL] [Abstract][Full Text] [Related]
14. Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review. Upshaw JN Curr Oncol Rep; 2020 Jun; 22(7):72. PubMed ID: 32564220 [TBL] [Abstract][Full Text] [Related]
15. Arterial hypertension in cancer: The elephant in the room. Tini G; Sarocchi M; Tocci G; Arboscello E; Ghigliotti G; Novo G; Brunelli C; Lenihan D; Volpe M; Spallarossa P Int J Cardiol; 2019 Apr; 281():133-139. PubMed ID: 30718135 [TBL] [Abstract][Full Text] [Related]
16. Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection. Hahn VS; Zhang KW; Sun L; Narayan V; Lenihan DJ; Ky B Circ Res; 2021 May; 128(10):1576-1593. PubMed ID: 33983833 [TBL] [Abstract][Full Text] [Related]
17. Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors. Patel S; Dushenkov A; Jungsuwadee P; Krishnaswami A; Barac A J Cardiovasc Transl Res; 2020 Jun; 13(3):463-477. PubMed ID: 32430701 [TBL] [Abstract][Full Text] [Related]
18. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. Nhola LF; Abdelmoneim SS; Villarraga HR; Kohli M; Grothey A; Bordun KA; Cheung M; Best R; Cheung D; Huang R; Barros-Gomes S; Pitz M; Singal PK; Jassal DS; Mulvagh SL J Am Soc Echocardiogr; 2019 Feb; 32(2):267-276. PubMed ID: 30459123 [TBL] [Abstract][Full Text] [Related]
19. Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment. Chuquin D; Abbate A; Bottinor W J Cardiovasc Pharmacol; 2022 Oct; 80(4):522-530. PubMed ID: 36027586 [TBL] [Abstract][Full Text] [Related]
20. Toxicities of targeted agents in advanced renal cell carcinoma. Patel P; Srinivas S Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]